Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty

P. K. Manasco, O. H. Pescovitz, P. P. Feuillan, K. D. Hench, K. M. Barnes, J. Jones, S. C. Hill, Donald (Lynn) Loriaux, G. B. Cutler

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

To determine whether puberty resumes normally after long term LHRH agonist (LHRHa) treatment, we studied 16 children with central precocious puberty treated with LHRHa (D-Trp6-Pro9,NEt-LHRH) for 1-4 yr (mean, 3.3 yr). Treatment was discontinued at a mean age of 11.6 ± 1.3 (± SD) yr. Plasma hormone levels, growth velocity, rate of bone maturation, and pubertal stage were assessed at the end of treatment and 3 and 12 months later. Basal plasma sex steroid and basal and LHRH-stimulated gonadotropin levels returned to near-pretreatment levels 3 months after discontinuation of therapy and were fully restored to pretreatment levels at 12 months. Growth velocity, which had been 7.8 cm/yr before treatment, was stable after discontinuation of treatment at approximately 2.6 cm/yr. The predicted height, which had increased during treatment (P <0.01), remained stable at approximately 5 cm above the pretreatment predicted height. The rate of bone age advancement (Δbone age/Δchronological age) increased gradually from 0.4 at the end of treatment to the normal value of 0.9 12 months posttreatment. Breast and pubic hair pubertal stages, which were stable throughout treatment and were 4.0 ± 0.8 (± SD) and 3.6 ± 1.0 at the end of treatment, increased to 4.9 ± 0.2 and 4.5 ± 1.0. This approximated the normal rate of 1 stage/yr. Menses occurred in 8 of 12 girls within 1 yr after treatment and in an additional 3 by 20 months after treatment. Six of the girls had menstruated before treatment, and all of these menstruated within 14 months after discontinuing therapy. We conclude that gonadotropin and sex steroid secretion and the clinical progression through puberty appear to resume normally after discontinuation of long term LHRHa treatment of central precocious puberty. Long term follow-up will be required, however, to determine whether the improvement in predicted height of these patients will be achieved, and whether adult reproductive function will be normal.

Original languageEnglish (US)
Pages (from-to)368-372
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume67
Issue number2
StatePublished - 1988
Externally publishedYes

Fingerprint

Puberty
Gonadotropin-Releasing Hormone
Bone
Gonadotropins
Steroids
Plasmas
Therapeutics
Central Precocious Puberty
Hormones
Bone and Bones
Menstruation
Hair
Growth Hormone
Reference Values
Breast

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Manasco, P. K., Pescovitz, O. H., Feuillan, P. P., Hench, K. D., Barnes, K. M., Jones, J., ... Cutler, G. B. (1988). Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. Journal of Clinical Endocrinology and Metabolism, 67(2), 368-372.

Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. / Manasco, P. K.; Pescovitz, O. H.; Feuillan, P. P.; Hench, K. D.; Barnes, K. M.; Jones, J.; Hill, S. C.; Loriaux, Donald (Lynn); Cutler, G. B.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 67, No. 2, 1988, p. 368-372.

Research output: Contribution to journalArticle

Manasco, PK, Pescovitz, OH, Feuillan, PP, Hench, KD, Barnes, KM, Jones, J, Hill, SC, Loriaux, DL & Cutler, GB 1988, 'Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty', Journal of Clinical Endocrinology and Metabolism, vol. 67, no. 2, pp. 368-372.
Manasco, P. K. ; Pescovitz, O. H. ; Feuillan, P. P. ; Hench, K. D. ; Barnes, K. M. ; Jones, J. ; Hill, S. C. ; Loriaux, Donald (Lynn) ; Cutler, G. B. / Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. In: Journal of Clinical Endocrinology and Metabolism. 1988 ; Vol. 67, No. 2. pp. 368-372.
@article{2da80040675a43b7882af29c1d3c7d56,
title = "Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty",
abstract = "To determine whether puberty resumes normally after long term LHRH agonist (LHRHa) treatment, we studied 16 children with central precocious puberty treated with LHRHa (D-Trp6-Pro9,NEt-LHRH) for 1-4 yr (mean, 3.3 yr). Treatment was discontinued at a mean age of 11.6 ± 1.3 (± SD) yr. Plasma hormone levels, growth velocity, rate of bone maturation, and pubertal stage were assessed at the end of treatment and 3 and 12 months later. Basal plasma sex steroid and basal and LHRH-stimulated gonadotropin levels returned to near-pretreatment levels 3 months after discontinuation of therapy and were fully restored to pretreatment levels at 12 months. Growth velocity, which had been 7.8 cm/yr before treatment, was stable after discontinuation of treatment at approximately 2.6 cm/yr. The predicted height, which had increased during treatment (P <0.01), remained stable at approximately 5 cm above the pretreatment predicted height. The rate of bone age advancement (Δbone age/Δchronological age) increased gradually from 0.4 at the end of treatment to the normal value of 0.9 12 months posttreatment. Breast and pubic hair pubertal stages, which were stable throughout treatment and were 4.0 ± 0.8 (± SD) and 3.6 ± 1.0 at the end of treatment, increased to 4.9 ± 0.2 and 4.5 ± 1.0. This approximated the normal rate of 1 stage/yr. Menses occurred in 8 of 12 girls within 1 yr after treatment and in an additional 3 by 20 months after treatment. Six of the girls had menstruated before treatment, and all of these menstruated within 14 months after discontinuing therapy. We conclude that gonadotropin and sex steroid secretion and the clinical progression through puberty appear to resume normally after discontinuation of long term LHRHa treatment of central precocious puberty. Long term follow-up will be required, however, to determine whether the improvement in predicted height of these patients will be achieved, and whether adult reproductive function will be normal.",
author = "Manasco, {P. K.} and Pescovitz, {O. H.} and Feuillan, {P. P.} and Hench, {K. D.} and Barnes, {K. M.} and J. Jones and Hill, {S. C.} and Loriaux, {Donald (Lynn)} and Cutler, {G. B.}",
year = "1988",
language = "English (US)",
volume = "67",
pages = "368--372",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty

AU - Manasco, P. K.

AU - Pescovitz, O. H.

AU - Feuillan, P. P.

AU - Hench, K. D.

AU - Barnes, K. M.

AU - Jones, J.

AU - Hill, S. C.

AU - Loriaux, Donald (Lynn)

AU - Cutler, G. B.

PY - 1988

Y1 - 1988

N2 - To determine whether puberty resumes normally after long term LHRH agonist (LHRHa) treatment, we studied 16 children with central precocious puberty treated with LHRHa (D-Trp6-Pro9,NEt-LHRH) for 1-4 yr (mean, 3.3 yr). Treatment was discontinued at a mean age of 11.6 ± 1.3 (± SD) yr. Plasma hormone levels, growth velocity, rate of bone maturation, and pubertal stage were assessed at the end of treatment and 3 and 12 months later. Basal plasma sex steroid and basal and LHRH-stimulated gonadotropin levels returned to near-pretreatment levels 3 months after discontinuation of therapy and were fully restored to pretreatment levels at 12 months. Growth velocity, which had been 7.8 cm/yr before treatment, was stable after discontinuation of treatment at approximately 2.6 cm/yr. The predicted height, which had increased during treatment (P <0.01), remained stable at approximately 5 cm above the pretreatment predicted height. The rate of bone age advancement (Δbone age/Δchronological age) increased gradually from 0.4 at the end of treatment to the normal value of 0.9 12 months posttreatment. Breast and pubic hair pubertal stages, which were stable throughout treatment and were 4.0 ± 0.8 (± SD) and 3.6 ± 1.0 at the end of treatment, increased to 4.9 ± 0.2 and 4.5 ± 1.0. This approximated the normal rate of 1 stage/yr. Menses occurred in 8 of 12 girls within 1 yr after treatment and in an additional 3 by 20 months after treatment. Six of the girls had menstruated before treatment, and all of these menstruated within 14 months after discontinuing therapy. We conclude that gonadotropin and sex steroid secretion and the clinical progression through puberty appear to resume normally after discontinuation of long term LHRHa treatment of central precocious puberty. Long term follow-up will be required, however, to determine whether the improvement in predicted height of these patients will be achieved, and whether adult reproductive function will be normal.

AB - To determine whether puberty resumes normally after long term LHRH agonist (LHRHa) treatment, we studied 16 children with central precocious puberty treated with LHRHa (D-Trp6-Pro9,NEt-LHRH) for 1-4 yr (mean, 3.3 yr). Treatment was discontinued at a mean age of 11.6 ± 1.3 (± SD) yr. Plasma hormone levels, growth velocity, rate of bone maturation, and pubertal stage were assessed at the end of treatment and 3 and 12 months later. Basal plasma sex steroid and basal and LHRH-stimulated gonadotropin levels returned to near-pretreatment levels 3 months after discontinuation of therapy and were fully restored to pretreatment levels at 12 months. Growth velocity, which had been 7.8 cm/yr before treatment, was stable after discontinuation of treatment at approximately 2.6 cm/yr. The predicted height, which had increased during treatment (P <0.01), remained stable at approximately 5 cm above the pretreatment predicted height. The rate of bone age advancement (Δbone age/Δchronological age) increased gradually from 0.4 at the end of treatment to the normal value of 0.9 12 months posttreatment. Breast and pubic hair pubertal stages, which were stable throughout treatment and were 4.0 ± 0.8 (± SD) and 3.6 ± 1.0 at the end of treatment, increased to 4.9 ± 0.2 and 4.5 ± 1.0. This approximated the normal rate of 1 stage/yr. Menses occurred in 8 of 12 girls within 1 yr after treatment and in an additional 3 by 20 months after treatment. Six of the girls had menstruated before treatment, and all of these menstruated within 14 months after discontinuing therapy. We conclude that gonadotropin and sex steroid secretion and the clinical progression through puberty appear to resume normally after discontinuation of long term LHRHa treatment of central precocious puberty. Long term follow-up will be required, however, to determine whether the improvement in predicted height of these patients will be achieved, and whether adult reproductive function will be normal.

UR - http://www.scopus.com/inward/record.url?scp=0023729472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023729472&partnerID=8YFLogxK

M3 - Article

C2 - 3292562

AN - SCOPUS:0023729472

VL - 67

SP - 368

EP - 372

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -